Provided is the use of a virosomal preparation comprising influenza hemagglutinin (HA) antigen wherein the preparation does not contain an additional adjuvant in the manufacture of an influenza vaccine for intradermal administration in human subjects. The preparation can comprise HA antigen from two or more influenza virus strains.